Stockscreener 앱 받기
44.06
0.52%
-0.095
전일 마감가:
$44.16
열려 있는:
$43.82
하루 거래량:
64,029
Relative Volume:
0.02
시가총액:
$11.60B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
24.90
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+0.71%
1개월 성능:
+2.09%
6개월 성능:
+27.33%
1년 성능:
+98.87%
1일 변동 폭
$43.80
$44.05
1주일 범위
$43.39
$48.74
52주 변동 폭
$21.86
$49.62
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
44.00 | 11.60B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.75 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
543.10 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.82 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.55 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
243.06 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2024-09-19 | 개시 | UBS | Neutral |
| 2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-12-19 | 개시 | BTIG Research | Buy |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-09-26 | 개시 | H.C. Wainwright | Buy |
| 2023-08-22 | 재확인 | Oppenheimer | Outperform |
| 2023-08-08 | 개시 | SVB Securities | Market Perform |
| 2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 재개 | Piper Sandler | Overweight |
| 2023-03-09 | 개시 | Wells Fargo | Overweight |
| 2023-01-26 | 개시 | Credit Suisse | Outperform |
| 2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
| 2022-06-24 | 개시 | BMO Capital Markets | Outperform |
| 2021-11-19 | 개시 | Piper Sandler | Overweight |
| 2021-11-03 | 재개 | Jefferies | Buy |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2021-06-15 | 개시 | H.C. Wainwright | Buy |
| 2021-05-18 | 재개 | Goldman | Sell |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 개시 | SunTrust | Buy |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2018-09-17 | 개시 | Goldman | Neutral |
| 2018-09-10 | 개시 | Morgan Stanley | Underweight |
| 2018-05-11 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | Needham | Buy |
| 2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-16 | 재확인 | SunTrust | Buy |
| 2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-12 | 재확인 | Needham | Buy |
| 2017-07-14 | 개시 | SunTrust | Buy |
| 2017-03-31 | 개시 | Needham | Buy |
| 2017-03-16 | 개시 | Oppenheimer | Perform |
| 2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
How to Take Advantage of moves in (EXEL) - news.stocktradersdaily.com
Exelixis’s SWOT analysis: cabozantinib’s strength, zanzalintinib’s potential drive stock outlook - Investing.com Canada
Zacks.com featured highlights include Flex, CVS Health, Urban Outfitters and Exelixis - Yahoo Finance
EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL S - GuruFocus
Exelixis stock maintains buy rating at H.C. Wainwright on promising data - Investing.com Canada
Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? - Yahoo Finance
Exelixis, Inc.'s (NASDAQ:EXEL) Stock's On An Uptrend: Are Strong Financials Guiding The Market? - simplywall.st
EXEL: HC Wainwright & Co. Raises Price Target to $47.00 | EXEL Stock News - GuruFocus
Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL S - GuruFocus
Promising Clinical Data and Favorable Safety Profile Drive Buy Rating for Exelixis - TipRanks
Exelixis (EXEL) Stock Target Boosted by H.C. Wainwright | EXEL Stock News - GuruFocus
Indexes Rise But Growth Plays Hit; Quanta Services, Exelixis, Google In Focus - Investor's Business Daily
Kalkine: Exelixis Joins Momentum Wave Ahead of Russell 1000 Rebalance - Kalkine Media
BofA Hikes Exelixis, Inc. (EXEL) Target Amid CRC Caution - MSN
3 Reasons Why Growth Investors Shouldn't Overlook Exelixis (EXEL) - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Robust Revenue Growth - DirectorsTalk Interviews
Exelixis, Inc. (NASDAQ:EXEL) Stock Holdings Increased by GAMMA Investing LLC - Defense World
Bank of America Forecasts Strong Price Appreciation for Exelixis (NASDAQ:EXEL) Stock - Defense World
Brokerages Set Exelixis, Inc. (NASDAQ:EXEL) Price Target at $38.94 - Defense World
Zacks Research Has Bullish Forecast for Exelixis Q2 Earnings - Defense World
Exelixis Escapes Cancer Drug Invalidity Bid At PTAB - Law360
Are You Looking for a Top Momentum Pick? Why Exelixis (EXEL) is a Great Choice - Yahoo Finance
Analyst Expectations For Exelixis's Future - Benzinga
Exelixis (EXEL) Sees Price Target Raised by B of A Securities | - GuruFocus
BofA Adjusts Price Target for Exelixis (EXEL) Amid Critical Pipe - GuruFocus
Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (E - GuruFocus
Director Jack Wyszomierski Sells 7,535 Shares of Exelixis Inc (EXEL) - GuruFocus
Exelixis at Jefferies Conference: Strategic Moves for Growth By Investing.com - Investing.com Canada
Exelixis Stock Surges 28% YTD: Should You Buy Now or Sell? - sharewise
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term - sharewise
Transcript : Exelixis, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 07 - MarketScreener
Exelixis Stock Surges 28% YTD: Should You Buy Now Or Sell? - Barchart.com
Stifel maintains hold rating on Exelixis stock, sets $38 target - Investing.com
Exelixis at 45th Annual William Blair Conference: Oncology Ambitions - Investing.com Australia
Transcript : Exelixis, Inc. Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 10 - MarketScreener
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis, Inc. (EXEL) Stock Analysis: Navigating Growth in the Biotech Space with Robust Revenue Momentum - DirectorsTalk Interviews
Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025 - Business Wire
2 Top Stocks to Buy With Less Than $100 - The Globe and Mail
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Transcript : Exelixis, Inc. Presents at TD Cowen's 6th Annual Oncology Innovation Summit, May-27-2025 02 - marketscreener.com
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Decreases Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with Promising Growth Potential - DirectorsTalk Interviews
EXEL Reports Superior Efficacy Data From Kidney Cancer Study Cohort - MSN
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress By Investing.com - Investing.com South Africa
Exelixis’s SWOT analysis: stock poised for growth amid oncology pipeline progress - Investing.com Australia
Deutsche Bank AG Has $1.54 Million Stake in Exelixis, Inc. (NASDAQ:EXEL) - Defense World
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Exelixis Inc 주식 (EXEL) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| WYSZOMIERSKI JACK L | Director |
Jun 03 '25 |
Sale |
43.09 |
7,535 |
324,683 |
358,882 |
2.66%
2.19%
자본화:
|
볼륨(24시간):